Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.
Identifieur interne : 004F07 ( Main/Exploration ); précédent : 004F06; suivant : 004F08Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.
Auteurs : Sharad Goyal [États-Unis] ; Malay S. Rao ; Atif Khan ; Lien Huzzy ; Camille Green ; Bruce G. HafftySource :
- International journal of radiation oncology, biology, physics [ 1879-355X ] ; 2011.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux humanisés, Bévacizumab, Dosimétrie en radiothérapie, Fatigue (étiologie), Femelle, Humains, Inhibiteurs de l'angiogenèse (administration et posologie), Inhibiteurs de l'angiogenèse (effets indésirables), Lymphoedème (étiologie), Pneumopathie infectieuse (étiologie), Pneumopathie radique (étiologie), Radiosensibilisants (administration et posologie), Radiosensibilisants (effets indésirables), Radiothérapie adjuvante (effets indésirables), Sujet âgé, Trastuzumab, Tumeurs du sein (anatomopathologie), Tumeurs du sein (radiothérapie), Tumeurs du sein (traitement médicamenteux), Études cas-témoins.
- MESH :
- administration et posologie : Anticorps monoclonaux, Inhibiteurs de l'angiogenèse, Radiosensibilisants.
- anatomopathologie : Tumeurs du sein.
- effets indésirables : Anticorps monoclonaux, Inhibiteurs de l'angiogenèse, Radiosensibilisants, Radiothérapie adjuvante.
- radiothérapie : Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- étiologie : Fatigue, Lymphoedème, Pneumopathie infectieuse, Pneumopathie radique.
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés, Bévacizumab, Dosimétrie en radiothérapie, Femelle, Humains, Sujet âgé, Trastuzumab, Études cas-témoins.
English descriptors
- KwdEn :
- Adult, Aged, Angiogenesis Inhibitors (administration & dosage), Angiogenesis Inhibitors (adverse effects), Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal, Humanized, Bevacizumab, Breast Neoplasms (drug therapy), Breast Neoplasms (pathology), Breast Neoplasms (radiotherapy), Case-Control Studies, Fatigue (etiology), Female, Humans, Lymphedema (etiology), Middle Aged, Pneumonia (etiology), Radiation Pneumonitis (etiology), Radiation-Sensitizing Agents (administration & dosage), Radiation-Sensitizing Agents (adverse effects), Radiotherapy Dosage, Radiotherapy, Adjuvant (adverse effects), Trastuzumab.
- MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Antibodies, Monoclonal, Radiation-Sensitizing Agents.
- chemical , adverse effects : Angiogenesis Inhibitors, Antibodies, Monoclonal, Radiation-Sensitizing Agents.
- adverse effects : Radiotherapy, Adjuvant.
- drug therapy : Breast Neoplasms.
- etiology : Fatigue, Lymphedema, Pneumonia, Radiation Pneumonitis.
- pathology : Breast Neoplasms.
- radiotherapy : Breast Neoplasms.
- Adult, Aged, Antibodies, Monoclonal, Humanized, Bevacizumab, Case-Control Studies, Female, Humans, Middle Aged, Radiotherapy Dosage, Trastuzumab.
Abstract
Preclinical studies have shown that bevacizumab combined with radiotherapy (RT) induces a radiosensitizing effect. Published reports regarding the safety of combination therapy involving bevacizumab and RT are lacking. The purpose of this study was to analyze acute locoregional toxicity in patients with breast cancer receiving concurrent bevacizumab plus RT.
DOI: 10.1016/j.ijrobp.2009.11.021
PubMed: 20452134
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A82
- to stream PubMed, to step Curation: 002A82
- to stream PubMed, to step Checkpoint: 002A82
- to stream Ncbi, to step Merge: 003A97
- to stream Ncbi, to step Curation: 003A97
- to stream Ncbi, to step Checkpoint: 003A97
- to stream Main, to step Merge: 004F43
- to stream Main, to step Curation: 004F07
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.</title><author><name sortKey="Goyal, Sharad" sort="Goyal, Sharad" uniqKey="Goyal S" first="Sharad" last="Goyal">Sharad Goyal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA. goyalsh@umdnj.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ 08903</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Rao, Malay S" sort="Rao, Malay S" uniqKey="Rao M" first="Malay S" last="Rao">Malay S. Rao</name></author><author><name sortKey="Khan, Atif" sort="Khan, Atif" uniqKey="Khan A" first="Atif" last="Khan">Atif Khan</name></author><author><name sortKey="Huzzy, Lien" sort="Huzzy, Lien" uniqKey="Huzzy L" first="Lien" last="Huzzy">Lien Huzzy</name></author><author><name sortKey="Green, Camille" sort="Green, Camille" uniqKey="Green C" first="Camille" last="Green">Camille Green</name></author><author><name sortKey="Haffty, Bruce G" sort="Haffty, Bruce G" uniqKey="Haffty B" first="Bruce G" last="Haffty">Bruce G. Haffty</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:20452134</idno><idno type="pmid">20452134</idno><idno type="doi">10.1016/j.ijrobp.2009.11.021</idno><idno type="wicri:Area/PubMed/Corpus">002A82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A82</idno><idno type="wicri:Area/PubMed/Curation">002A82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A82</idno><idno type="wicri:Area/PubMed/Checkpoint">002A82</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A82</idno><idno type="wicri:Area/Ncbi/Merge">003A97</idno><idno type="wicri:Area/Ncbi/Curation">003A97</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A97</idno><idno type="wicri:Area/Main/Merge">004F43</idno><idno type="wicri:Area/Main/Curation">004F07</idno><idno type="wicri:Area/Main/Exploration">004F07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.</title><author><name sortKey="Goyal, Sharad" sort="Goyal, Sharad" uniqKey="Goyal S" first="Sharad" last="Goyal">Sharad Goyal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA. goyalsh@umdnj.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ 08903</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Rao, Malay S" sort="Rao, Malay S" uniqKey="Rao M" first="Malay S" last="Rao">Malay S. Rao</name></author><author><name sortKey="Khan, Atif" sort="Khan, Atif" uniqKey="Khan A" first="Atif" last="Khan">Atif Khan</name></author><author><name sortKey="Huzzy, Lien" sort="Huzzy, Lien" uniqKey="Huzzy L" first="Lien" last="Huzzy">Lien Huzzy</name></author><author><name sortKey="Green, Camille" sort="Green, Camille" uniqKey="Green C" first="Camille" last="Green">Camille Green</name></author><author><name sortKey="Haffty, Bruce G" sort="Haffty, Bruce G" uniqKey="Haffty B" first="Bruce G" last="Haffty">Bruce G. Haffty</name></author></analytic><series><title level="j">International journal of radiation oncology, biology, physics</title><idno type="eISSN">1879-355X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Angiogenesis Inhibitors (administration & dosage)</term><term>Angiogenesis Inhibitors (adverse effects)</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal, Humanized</term><term>Bevacizumab</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (radiotherapy)</term><term>Case-Control Studies</term><term>Fatigue (etiology)</term><term>Female</term><term>Humans</term><term>Lymphedema (etiology)</term><term>Middle Aged</term><term>Pneumonia (etiology)</term><term>Radiation Pneumonitis (etiology)</term><term>Radiation-Sensitizing Agents (administration & dosage)</term><term>Radiation-Sensitizing Agents (adverse effects)</term><term>Radiotherapy Dosage</term><term>Radiotherapy, Adjuvant (adverse effects)</term><term>Trastuzumab</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Anticorps monoclonaux (effets indésirables)</term><term>Anticorps monoclonaux humanisés</term><term>Bévacizumab</term><term>Dosimétrie en radiothérapie</term><term>Fatigue (étiologie)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (administration et posologie)</term><term>Inhibiteurs de l'angiogenèse (effets indésirables)</term><term>Lymphoedème (étiologie)</term><term>Pneumopathie infectieuse (étiologie)</term><term>Pneumopathie radique (étiologie)</term><term>Radiosensibilisants (administration et posologie)</term><term>Radiosensibilisants (effets indésirables)</term><term>Radiothérapie adjuvante (effets indésirables)</term><term>Sujet âgé</term><term>Trastuzumab</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (radiothérapie)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études cas-témoins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal</term><term>Radiation-Sensitizing Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal</term><term>Radiation-Sensitizing Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Inhibiteurs de l'angiogenèse</term><term>Radiosensibilisants</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radiotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Inhibiteurs de l'angiogenèse</term><term>Radiosensibilisants</term><term>Radiothérapie adjuvante</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fatigue</term><term>Lymphedema</term><term>Pneumonia</term><term>Radiation Pneumonitis</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Fatigue</term><term>Lymphoedème</term><term>Pneumopathie infectieuse</term><term>Pneumopathie radique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized</term><term>Bevacizumab</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Radiotherapy Dosage</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés</term><term>Bévacizumab</term><term>Dosimétrie en radiothérapie</term><term>Femelle</term><term>Humains</term><term>Sujet âgé</term><term>Trastuzumab</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Preclinical studies have shown that bevacizumab combined with radiotherapy (RT) induces a radiosensitizing effect. Published reports regarding the safety of combination therapy involving bevacizumab and RT are lacking. The purpose of this study was to analyze acute locoregional toxicity in patients with breast cancer receiving concurrent bevacizumab plus RT.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>New Jersey</li></region></list><tree><noCountry><name sortKey="Green, Camille" sort="Green, Camille" uniqKey="Green C" first="Camille" last="Green">Camille Green</name><name sortKey="Haffty, Bruce G" sort="Haffty, Bruce G" uniqKey="Haffty B" first="Bruce G" last="Haffty">Bruce G. Haffty</name><name sortKey="Huzzy, Lien" sort="Huzzy, Lien" uniqKey="Huzzy L" first="Lien" last="Huzzy">Lien Huzzy</name><name sortKey="Khan, Atif" sort="Khan, Atif" uniqKey="Khan A" first="Atif" last="Khan">Atif Khan</name><name sortKey="Rao, Malay S" sort="Rao, Malay S" uniqKey="Rao M" first="Malay S" last="Rao">Malay S. Rao</name></noCountry><country name="États-Unis"><region name="New Jersey"><name sortKey="Goyal, Sharad" sort="Goyal, Sharad" uniqKey="Goyal S" first="Sharad" last="Goyal">Sharad Goyal</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004F07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20452134
|texte= Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20452134" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |